Mayo Clinic launches intelligent PSA control tower for prostate cancer care

UAE—Mayo Clinic has introduced the PSA Control Tower, an intelligent monitoring system designed to improve follow-up care for prostate cancer patients after treatment.

Developed by the institution’s Department of Radiation Oncology, the new tool aims to help clinicians track patient recovery more efficiently while enabling faster responses to potential signs of recurrence.

The launch comes as healthcare systems worldwide face growing pressure to manage rising cancer patient volumes while maintaining personalized, high-quality care.

Recent updates to prostate cancer management guidelines from the American Urological Association and the American Society for Radiation Oncology have also reinforced the need for more precise, risk-based follow-up strategies.

Traditionally, clinicians monitor prostate cancer patients through scheduled follow-up appointments and manual reviews of prostate-specific antigen (PSA) test results.

While effective, this process often consumes significant administrative time and may delay clinical intervention when subtle but meaningful changes in PSA levels emerge.

Because PSA trends provide one of the earliest indicators of possible cancer recurrence, timely interpretation of these fluctuations remains critical.

However, as patient numbers continue to rise, consistent monitoring has become increasingly difficult for already stretched care teams.

How the PSA Control Tower works

The PSA Control Tower addresses these challenges by combining PSA trends with broader clinical data to help identify patients who may require immediate attention.

Instead of replacing physician judgment, the platform supports clinicians by flagging concerning patterns earlier and streamlining the review process.

Built on the Mayo Clinic Platform, the system operates within a secure environment where Mayo Clinic teams can access large volumes of de-identified patient data.

This allows researchers to analyze long-term patterns and train predictive models using laboratory results, pathology reports, imaging records, and physician notes.

“Our hope is that the PSA Control Tower will be a rare win-win-win for patients, physicians and hospital systems,” said Dr. Mark Waddle, a radiation oncologist at Mayo Clinic.

He added that the system enables around-the-clock monitoring, helping ensure abnormal PSA values receive prompt clinical review.

Supporting precision oncology

As new data flows into the platform, its predictive models continuously improve, giving clinicians access to clear dashboards that display PSA trajectories and recurrence risk in real time.

The innovation aligns with Mayo Clinic’s Bold. Forward. precision oncology strategy, which focuses on integrating advanced analytics with clinical workflows.

Mayo Clinic officials say the platform could eventually expand beyond its own facilities, enabling broader adoption of data-driven prostate cancer monitoring across healthcare systems nationwide.

Dr. Waddle noted that the tool allows specialists to devote more time to newly diagnosed and complex cases while focusing follow-up resources on patients who need the highest level of attention.